Joincare Pharmaceutical Acquires Rights to TaiGen’s PA Endonuclease Inhibitor TG-1000
China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced a licensing agreement with...
March 2023
Reistone Biopharma’s Ivarmacitinib Shows Positive Results in Phase III QUARTZ3 Study
Reistone Biopharma Co., Ltd, incubated by Hengrui Pharmaceuticals (SHA: 600276) with USD 100 million in...
Sinopharm Forms Joint Ventures with Foreign Medical Equipment Firms
Sinopharm China National Biotech Group Co., Ltd (CNBG) has announced partnerships with two foreign medical...
BeiGene Marks Topping Off of New Biologics Facility in New Jersey
China-based biotech BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) held a ceremony to mark the...
Roche Partners with China Resource Medicine to Promote Xofluza in China
Swiss pharmaceutical giant Roche (SWX: ROG) has entered into a partnership with China-based China Resource...
Jacobio Pharma Partners with Merck to Evaluate CD73 mAb and Keytruda Combination
China-based Jacobio Pharma (HKG: 1167) has announced a clinical partnership with Merck, Sharp & Dohme...
Yifan Pharmaceutical’s F-652 Cleared for Phase II Trial in Alcoholic Hepatitis
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) has announced that its subsidiary Evive Biotech Ltd’s...
BioNTech Acquires Global Rights to OncoC4’s Anti-CTLA-4 Antibody ONC-392
Germany-based mRNA specialist BioNTech SE (NASDAQ: BNTX) has unveiled a licensing deal and collaboration with...
Cygnus Bio Raises Millions in Series C+ Financing for Sequencing Technology
Beijing-based second-generation sequencing technology platform Cygnus Bio has reportedly raised “hundreds of millions” of renminbi...
L&L Biopharma Completes Series B Financing for Tumor Immunotherapy Development
Shanghai-based tumor immunotherapy developer L&L Biopharma Co., Ltd has announced the completion of a Series...
T&L Biotechnology Secures RMB 100 Million in Series A Financing
Beijing-based cell and gene therapy (CGT) developer T&L Biotechnology Co., Ltd has reportedly raised RMB...
Yiling Pharmaceutical’s BIO-008 Receives NMPA Approval for Clinical Trials
China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced that it has received clinical trial...
Hengrui Pharmaceuticals’ SHR8028 Receives NMPA Review for Dry Eye Treatment
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that a market approval filing...
LBX Pharmacy Partners with Gilead Sciences to Enhance Disease Management in China
China-based LBX Pharmacy has entered into a partnership with US-based Gilead Sciences, Inc (NASDAQ: GILD)....
Jiangsu Recbio’s ReCOV Vaccine Receives Emergency Use Authorization in Mongolia
China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) has announced that it has...
WuXi AppTec Reports 71.8% Revenue Growth in 2022 Financials
China-based WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) released its 2022 financial report, recording...
Luye Pharma’s BA1102 Biosimilar to Xgeva Accepted for CDE Review
China-based Luye Pharma Group (HKG: 2186) has announced that a market approval filing for its...
Bayer’s Nubeqa Receives Additional NMPA Approval for mHSPC Treatment-Fineline Info & Tech
German pharmaceutical giant Bayer AG (ETR: BAYN) has announced that it has received another indication...
NMPA Denies Market Approval for Hengrui’s Plinabulin in Chemotherapy-Induced Neutropenia
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) announced in a stock exchange statement that the...
SciClone Pharmaceuticals’ Vaborem Approved for Phase III Clinical Trial in China
SciClone Pharmaceuticals Inc (HKG: 6600) has announced that a clinical trial filing for its Vaborem...